A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
Status:
Active, not recruiting
Trial end date:
2022-08-18
Target enrollment:
Participant gender:
Summary
This study will characterize the movement of drugs within the body, evaluate safety and
determine to which extent the body can process relatlimab in combination with nivolumab in
subjects with certain advanced tumors